Targeting Oxidative Stress in Chronic Beryllium Disease

NCT01088243 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

COMPLETED

Status

18

Enrollment

OTHER

Sponsor class

Conditions

Chronic Beryllium Disease

Interventions

DRUG: Mesalamine
DRUG: Placebo

Sponsor

National Jewish Health